NASDAQ, HRMY End of Day and Historical Stock Data [Harmony Biosciences Holdings Inc]

The worlds #1 website for end of day & historical stock data

wide range of exchanges, data formats, tools and services

APINEW HISTORICAL DATA SYMBOL LISTS MEMBERSHIP REGISTER LOG IN

NASDAQ, HRMY:

28 Aug 2025

LAST: 37.97	CHANGE: 0.88	OPEN: 38.02	HIGH: 38.21	ASK: 0.00	VOLUME: 426.4K
LAST: 37.97	CHG(%): 2.37	PREV: 37.17	LOW: 37.63	BID: 0.00

CHART

Period:

RECENT END OF DAY PRICES

Date	Open	High	Low	Close	Volume
28 Aug 25	38.02	38.21	37.63	37.97	426.4K
27 Aug 25	37.17	38.28	37.17	38.05	500.6K
26 Aug 25	37.41	37.53	37.02	37.17	271.4K
25 Aug 25	38.00	38.25	37.27	37.42	399.9K
22 Aug 25	37.45	38.06	37.28	37.86	491.9K
21 Aug 25	36.67	37.65	36.62	37.29	536.3K
20 Aug 25	36.39	36.64	36.08	36.63	459.5K
19 Aug 25	36.43	36.81	36.15	36.40	417.5K
18 Aug 25	36.92	37.46	36.39	36.41	478.7K
15 Aug 25	36.48	36.95	36.15	36.87	450.5K

COMPANY PROFILE

Name:
About:	Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Sector:	Healthcare
Industry:	Biotechnology
Address:	630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
Website:	https://www.harmonybiosciences.com
CUSIP:	413197104
CIK:	0001802665
ISIN:	US4131971040
FIGI:	BBG00WBPG4C2

SYMBOL HISTORY

Purchase End of Day History
for this symbol from Jan 01, 0001

Purchase Intraday History
for this symbol from Jan 01, 0001

Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

Exchange:

Format:

Period:

Zip file

Symbol:

Start Date:

End Date:

FUNDAMENTALS

P/E Ratio:	11.74
PtB:	2.71
PtS:	2.71
EBITDA:	245.73M
Shares:	57.53M
Market Cap:	2.185B

TECHNICAL INDICATORS

MA5:	37.56
MA10:	37.06
MA20:	36.03
MA50:	34.78
MA100:	33.59
MA200:	34.24
STO9:	87.77
STO14:	94.38
RSI14:	79.69
MTM14:	3.86
ROC14:	0.11
ATR:	0.85
Week High:	38.28
Week Low:	36.08
Month High:	38.28
Month Low:	32.64
Year High:	41.61
Year Low:	26.47
Volatility:	33.71